ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Molecular predictors of recurrence in vestibular schwannomas: a transcriptomic and RT-qPCR analysis.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeVestibular schwannomas (VS) are benign tumors with variable clinical behavior. Recurrence after surgery is uncommon yet sometimes aggressive. Reliable molecular predictors of recurrence are lacking, and the correlation between genotype and phenotype is weak. This study aimed to identify molecular markers associated with recurrence in VS and explore their prognostic potential.
methodsRetrospective case-control study of patients undergoing VS surgery between 2017 and 2024. RNA-Seq was conducted to identify molecular signatures associated with recurrence, and selected genes were validated using RT-qPCR. Recurrence-free and salvage surgery-free survival were analyzed by the extent of resection.
results23 samples from 22 patients were analyzed, including 7 recurrent and 16 non-recurrent cases. 81 differentially expressed genes were identified in recurrent tumors, with enrichment of the MAPK (FDR = 7.9 × 10⁻⁴) and PI3K/AKT/mTOR (FDR = 0.038) pathways. Eight candidate genes were selected for validation: DCN (FC 4.34); DUSP5 (FC 4.20); CXCL8 (FC 3.25); JUND (FC 3.27); MYC (FC 2.45); MAFF (FC 3.79); SOD3 (FC 2.47) (all upregulated), and TNF (FC 0.16) (downregulated). RT-qPCR confirmed that CXCL8 and TNF were significantly elevated in tumors requiring early salvage surgery and in an NF2-associated Schwannomatosis case. No differences in recurrence-free or salvage surgery-free survival were observed between near-total and subtotal resections.
conclusionRecurrent VS exhibit a distinct molecular profile, highlighting IL-8 and TNFα as potential biomarkers and therapeutic targets. These findings support the development of a prognostic panel to guide personalized follow-up and treatment, particularly for high-risk patients. Further studies are needed before clinical implementation.
Indexed as
Identifiers
42642532What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.